$25.15
0.251.00%
At Close: -
$25.07
-0.08-0.32%
After Hours: 9:25 AM EDT
15 minutes delayed
Genmab
GMABNASDAQ
Genmab (NASDAQ:GMAB) Stock, Analyst Ratings, Price Targets, Predictions
Genmab A/S has a consensus price target of $28.08, established from looking at the 72 latest analyst ratings. The last 3 analyst ratings were released from BTIG, HC Wainwright & Co., and HC Wainwright & Co. on June 27, 2024, June 27, 2024, and June 20, 2024. With an average price target of $49 between BTIG, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 95.45% upside for Genmab A/S from these 3 analyst ratings.
Analyst Firms Making Recommendations1
BTIG
HC Wainwright & Co.
Truist Securities
Morgan Stanley
BMO Capital
1calculated from analyst ratings
Analyst Ratings for Genmab
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/27/2024 | Buy Now | 87.48% | BTIG | Kaveri Pohlman | $46 → $47 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 99.44% | HC Wainwright & Co. | Raghuram Selvaraju | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | 99.44% | HC Wainwright & Co. | Raghuram Selvaraju | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 06/04/2024 | Buy Now | 111.41% | Truist Securities | Asthika Goonewardene | $50 → $53 | Maintains | Buy | Get Alert |
| 06/03/2024 | Buy Now | 99.44% | HC Wainwright & Co. | Raghuram Selvaraju | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/20/2024 | Buy Now | 99.44% | HC Wainwright & Co. | Raghuram Selvaraju | → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 99.44% | HC Wainwright & Co. | Raghuram Selvaraju | → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | 99.44% | HC Wainwright & Co. | Raghuram Selvaraju | → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/04/2024 | Buy Now | 99.44% | HC Wainwright & Co. | Raghuram Selvaraju | → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 99.44% | HC Wainwright & Co. | Raghuram Selvaraju | $50 → $50 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | 27.64% | Morgan Stanley | Matthew Harrison | $32 → $32 | Maintains | Underweight | Get Alert |
| 03/26/2024 | Buy Now | 99.44% | Truist Securities | Asthika Goonewardene | $50 → $50 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 99.44% | HC Wainwright & Co. | Raghuram Selvaraju | → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | 91.46% | BMO Capital | Etzer Darout | $46 → $48 | Upgrade | Market Perform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | 99.44% | Truist Securities | Asthika Goonewardene | $54 → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2024 | Buy Now | 99.44% | HC Wainwright & Co. | Raghuram Selvaraju | → $50 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2024 | Buy Now | 99.44% | HC Wainwright & Co. | Raghuram Selvaraju | $49 → $50 | Maintains | Buy | Get Alert |
| 11/28/2023 | Buy Now | 95.45% | HC Wainwright & Co. | Raghuram Selvaraju | → $49 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | Buy Now | 95.45% | HC Wainwright & Co. | Raghuram Selvaraju | → $49 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | Buy Now | 27.64% | Morgan Stanley | Matthew Harrison | $33 → $32 | Maintains | Underweight | Get Alert |
| 11/08/2023 | Buy Now | 95.45% | HC Wainwright & Co. | Raghuram Selvaraju | $51 → $49 | Maintains | Buy | Get Alert |
| 10/18/2023 | Buy Now | 103.43% | HC Wainwright & Co. | Raghuram Selvaraju | → $51 | Reiterates | Buy → Buy | Get Alert |
| 10/13/2023 | Buy Now | 83.49% | BTIG | Kaveri Pohlman | $44 → $46 | Maintains | Buy | Get Alert |
| 09/26/2023 | Buy Now | 115.4% | Truist Securities | Asthika Goonewardene | → $54 | Reiterates | Buy → Buy | Get Alert |
| 09/06/2023 | Buy Now | 115.4% | Truist Securities | Asthika Goonewardene | → $54 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | Buy Now | 103.43% | HC Wainwright & Co. | Raghuram Selvaraju | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/24/2023 | Buy Now | 75.51% | BTIG | Kaveri Pohlman | → $44 | Initiates | → Buy | Get Alert |
| 08/15/2023 | Buy Now | 103.43% | HC Wainwright & Co. | Raghuram Selvaraju | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | 31.63% | Morgan Stanley | Matthew Harrison | $33 → $33 | Reiterates | Underweight → Underweight | Get Alert |
| 08/04/2023 | Buy Now | 103.43% | HC Wainwright & Co. | Raghuram Selvaraju | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | 31.63% | Morgan Stanley | Matthew Harrison | $33 → $33 | Reiterates | Underweight → Underweight | Get Alert |
| 07/31/2023 | Buy Now | 31.63% | Morgan Stanley | Matthew Harrison | $33 → $33 | Reiterates | Underweight → Underweight | Get Alert |
| 07/31/2023 | Buy Now | 103.43% | HC Wainwright & Co. | Raghuram Selvaraju | → $51 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | Buy Now | 31.63% | Morgan Stanley | Matthew Harrison | $33 → $33 | Reiterates | Underweight → Underweight | Get Alert |
| 07/17/2023 | Buy Now | 31.63% | Morgan Stanley | Matthew Harrison | $33 → $33 | Reiterates | Underweight → Underweight | Get Alert |
| 07/11/2023 | Buy Now | 115.4% | Truist Securities | Asthika Goonewardene | → $54 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2023 | Buy Now | 103.43% | HC Wainwright & Co. | Raghuram Selvaraju | → $51 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2023 | Buy Now | 31.63% | Morgan Stanley | Matthew Harrison | $33 → $33 | Reiterates | Underweight → Underweight | Get Alert |
| 06/26/2023 | Buy Now | 103.43% | HC Wainwright & Co. | Raghuram Selvaraju | → $51 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2023 | Buy Now | 31.63% | Morgan Stanley | Matthew Harrison | → $33 | Reiterates | → Underweight | Get Alert |
| 06/14/2023 | Buy Now | 103.43% | HC Wainwright & Co. | Raghuram Selvaraju | → $51 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | Buy Now | 31.63% | Morgan Stanley | Matthew Harrison | → $33 | Reiterates | → Underweight | Get Alert |
| 06/06/2023 | Buy Now | 103.43% | HC Wainwright & Co. | Raghuram Selvaraju | → $51 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | Buy Now | 103.43% | HC Wainwright & Co. | Raghuram Selvaraju | $47 → $51 | Maintains | Buy | Get Alert |
| 05/16/2023 | Buy Now | 87.48% | HC Wainwright & Co. | Raghuram Selvaraju | $46 → $47 | Maintains | Buy | Get Alert |
| 04/20/2023 | Buy Now | 83.49% | HC Wainwright & Co. | Raghuram Selvaraju | → $46 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | Buy Now | 83.49% | HC Wainwright & Co. | Raghuram Selvaraju | $51 → $46 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | 31.63% | Morgan Stanley | Matthew Harrison | $34 → $33 | Maintains | Underweight | Get Alert |
| 02/23/2023 | Buy Now | 35.62% | Morgan Stanley | Matthew Harrison | $35 → $34 | Maintains | Underweight | Get Alert |
| 02/06/2023 | Buy Now | 43.6% | SVB Leerink | — | $33 → $36 | Maintains | Market Perform | Get Alert |
| 01/24/2023 | Buy Now | 39.61% | Morgan Stanley | Matthew Harrison | $34 → $35 | Maintains | Underweight | Get Alert |
| 11/14/2022 | Buy Now | — | William Blair | Matt Phipps | — | Initiates | → Market Perform | Get Alert |
| 11/14/2022 | Buy Now | 35.62% | Morgan Stanley | Matthew Harrison | $31 → $34 | Maintains | Underweight | Get Alert |
| 11/10/2022 | Buy Now | 31.63% | SVB Leerink | Jonathan Chang | $31 → $33 | Maintains | Market Perform | Get Alert |
| 08/22/2022 | Buy Now | 103.43% | HC Wainwright & Co. | Raghuram Selvaraju | $49 → $51 | Maintains | Buy | Get Alert |
| 08/15/2022 | Buy Now | 23.65% | Morgan Stanley | Matthew Harrison | $29 → $31 | Maintains | Underweight | Get Alert |
| 08/11/2022 | Buy Now | 23.65% | SVB Leerink | Jonathan Chang | $30 → $31 | Maintains | Market Perform | Get Alert |
| 07/20/2022 | Buy Now | 95.45% | HC Wainwright & Co. | Raghuram Selvaraju | $47 → $49 | Maintains | Buy | Get Alert |
| 06/24/2022 | Buy Now | 38.53% | BMO Capital | Etzer Darout | → $34.73 | Initiates | → Market Perform | Get Alert |
| 05/17/2022 | Buy Now | 15.68% | Morgan Stanley | Matthew Harrison | $30 → $29 | Maintains | Underweight | Get Alert |
| 05/12/2022 | Buy Now | 19.66% | SVB Leerink | Jonathan Chang | $39 → $30 | Maintains | Market Perform | Get Alert |
| 05/02/2022 | Buy Now | 51.58% | Cowen & Co. | Yaron Werber | → $38 | Initiates | → Market Perform | Get Alert |
| 04/12/2022 | Buy Now | 19.66% | Morgan Stanley | Matthew Harrison | $33 → $30 | Maintains | Underweight | Get Alert |
| 02/17/2022 | Buy Now | 55.56% | SVB Leerink | Jonathan Chang | $42 → $39 | Maintains | Market Perform | Get Alert |
| 01/31/2022 | Buy Now | 87.48% | HC Wainwright & Co. | Raghuram Selvaraju | → $47 | Upgrade | Neutral → Buy | Get Alert |
| 01/03/2022 | Buy Now | — | Guggenheim | Michael Schmidt | — | Downgrade | Buy → Neutral | Get Alert |
| 12/01/2021 | Buy Now | — | Berenberg | Xian Deng | — | Initiates | → Sell | Get Alert |
| 09/16/2021 | Buy Now | — | Jefferies | Peter Welford | — | Downgrade | Buy → Hold | Get Alert |
| 09/07/2021 | Buy Now | 47.59% | Morgan Stanley | Matthew Harrison | — | Downgrade | Equal-Weight → Underweight | Get Alert |
| 08/24/2021 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Downgrade | Buy → Neutral | Get Alert |
| 08/12/2021 | Buy Now | 99.44% | Truist Securities | Asthika Goonewardene | $47 → $50 | Maintains | Buy | Get Alert |
| 08/12/2021 | Buy Now | 67.53% | SVB Leerink | Jonathan Chang | — | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Genmab (GMAB) stock?
The latest price target for Genmab (NASDAQ:GMAB) was reported by BTIG on June 27, 2024. The analyst firm set a price target for $47.00 expecting GMAB to rise to within 12 months (a possible 87.48% upside). 36 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Genmab (GMAB)?
The latest analyst rating for Genmab (NASDAQ:GMAB) was provided by BTIG, and Genmab maintained their buy rating.
When was the last upgrade for Genmab (GMAB)?
The last upgrade for Genmab A/S happened on February 23, 2024 when BMO Capital raised their price target to $48. BMO Capital previously had a market perform for Genmab A/S.
When was the last downgrade for Genmab (GMAB)?
The last downgrade for Genmab A/S happened on January 3, 2022 when Guggenheim changed their price target from N/A to N/A for Genmab A/S.
When is the next analyst rating going to be posted or updated for Genmab (GMAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.
Is the Analyst Rating Genmab (GMAB) correct?
While ratings are subjective and will change, the latest Genmab (GMAB) rating was a maintained with a price target of $46.00 to $47.00. The current price Genmab (GMAB) is trading at is $25.07, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.